VOR News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

VO

Mkt Cap

$1.14B

Volume

615.22K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio announced the grant of stock options for 59,250 shares and RSUs for 12,550 shares to 9 newly hired employees on October 1, 2026, as material inducements to employment. The options have a 10-year term with an exercise price of $18.06 per share and vest over four years. The company continues advancing telitacicept through Phase 3 clinical development for autoimmune diseases, with enrollment completed in the UPSTREAM MG trial and expansion into ocular myasthenia gravis.GlobeNewswire Inc. · Oct 5, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio announced on July 1, 2026, that it granted stock options to purchase 71,200 shares and RSUs representing 15,150 shares to 7 newly hired employees as material inducements to employment. The options have a 10-year term with an exercise price of $18.39 per share and vest over four years, with RSUs vesting quarterly over the same period.GlobeNewswire Inc. · Jul 2, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio announced the grant of stock options to purchase 61,050 shares and RSUs representing 12,900 shares to 10 newly hired employees on June 1, 2026. The stock options have a 10-year term with an exercise price of $14.57 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The RSUs also vest over four years with similar terms but quarterly vesting for the remaining shares.GlobeNewswire Inc. · Jun 1, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio announced the grant of stock options to purchase 42,650 shares and RSUs representing 9,050 shares to 9 newly hired employees on April 1, 2026. The stock options have a 10-year term with an exercise price of $17.39 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The grants were made as material inducements to employment under the company's 2023 Inducement Plan.GlobeNewswire Inc. · Apr 1, 2026

Vor Bio Announces Pricing of Public Offering of $100 Million of Common StockVor Biopharma is conducting a public offering of 10 million shares at $10 per share, expecting to raise $100 million. The offering includes an option for underwriters to purchase an additional 1.5 million shares.GlobeNewswire Inc. · Nov 11, 2025

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in ChinaTelitacicept demonstrated a 55% reduction in proteinuria and statistically significant improvements in kidney function during a Phase 3 clinical trial for IgA Nephropathy in China, with a favorable safety profile.GlobeNewswire Inc. · Nov 8, 2025

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Vor Bio granted stock options and restricted stock units to 20 newly hired employees on October 15, 2025, with options vesting over a four-year period and an exercise price of $30.22 per share.GlobeNewswire Inc. · Oct 31, 2025

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Vor Bio granted stock options and restricted stock units to seven newly hired employees under their 2023 Inducement Plan, with options vesting over a four-year period.GlobeNewswire Inc. · Aug 18, 2025

Vor Bio Announces $175 Million Private PlacementVor Bio has entered into a securities purchase agreement for a private placement financing expected to raise approximately $175 million through the issuance of prefunded warrants, with participation from several investment firms.GlobeNewswire Inc. · Jun 25, 2025

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of DirectorsVor Bio, a clinical-stage cell and genome engineering company, has appointed Erez Kalir, a life sciences and technology investor and entrepreneur, to its Board of Directors. Kalir's extensive experience in the biotech sector and track record of fostering innovation will be valuable as Vor Bio continues to execute its strategic vision.GlobeNewswire Inc. · Jan 8, 2025

VO

VORVor Biopharma Inc. Common Stock

VOR

Pay with—

Available Balance0.00

Your PositionYou don't own any VOR yet.

Related Tickers

Earnings